newsfilter
← Latest News
Business Wire·

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentationsSignatera™ Genome with Phased and Structural Variants, which has achieved detection below 1 part per 10 million and an LOD95 of